<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) May 19, 2000.
-------------
PHARMAPRINT INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Delaware 000-21141 33-0640125
- --------------------------------------------------------------------------------
(State or other jurisdic- (Commission File Number) (IRS Employer
tion of incorporation) Identification No.)
2600 Michelson Drive, Ste. 1600, Irvine, CA 92612
- ------------------------------------------- ----------
(Address of principle executive offices) (Zip Code)
Registrant's telephone number, including area code 949-794-7778
------------
N/A
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
----------
<PAGE>
Item 4. Changes in Registrant's Certifying Accountant
On May 19, 2000, the board of directors of PharmaPrint Inc. (the
"Company") approved the dismissal of Arthur Andersen LLP (the "Former Auditor"),
the principal accountant previously engaged to audit the Company's financial
statements. During the Company's two most recent fiscal years and the subsequent
period, the principal accountant's report on the Company's financial statements
did not contain an adverse opinion, disclaimer or qualification with respect to
uncertainty, audit scope or accounting principles. During the Company's two most
recent fiscal years and the subsequent period, there were no disagreements with
the Former Auditor on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope of procedures, which
disagreement, if not resolved to the satisfaction of the Former Auditor, would
have caused it to make reference to the subject matter of the disagreement in
connection with its report.
On May 18, 2000, the board of directors of the Company approved the
engagement of Corbin & Wertz as the principal accountant to audit the Company's
financial statements. During the Company's two most recent fiscal years and the
subsequent period prior to such appointment, the Company has not consulted the
newly engaged accountant regarding either the application of accounting
principles to a specified transaction or the type of audit opinion that might be
rendered on the Company's financial statements, nor on any matter that was
either the subject of a disagreement or a reportable event.
The Former Auditor reviewed the disclosure provided in this Current
Report on Form 8-K prior to its filing with the Securities and Exchange
Commission.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMAPRINT INC.
Date: May 19, 2000 By:/S/ STEVEN A. BOWMAN
-------------------------------
Name: Steven A. Bowman
Title: Chief Executive Officer
<PAGE>
EXHIBIT 16
May 19, 2000
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
RE: PHARMAPRINT INC.
COMMISSION FILE NO.
Dear Sir or Madam:
We were previously the principal accountant for PharmaPrint Inc. On May
12, 2000, our appointment as principal accountant was terminated. We have read
PharmaPrint Inc.'s statements, included under Item 4 of its Form 8-K dated May
19, 2000, and agree with such statements.
Very truly yours,
/S/ ARTHUR ANDERSEN LLP
- -----------------------
Arthur Andersen LLP
